Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza
Rivals’ Revenues Could Overtake Spinraza In 2023
New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.
You may also be interested in...
The clinical development head of Novartis Gene Therapies talks about the progress for SMA patients more than seven years after treatment began, and hopes of boosting outcomes by treating pre-symptomatic patients.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.